Associate Director CMC Drug Substance
Celldex Therapeutics
Associate Director CMC Drug Substance
Celldex Therapeutics
Develops antibody-based therapies targeting inflammatory diseases
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. We have built a culture where innovative and talented people thrive—focusing a significant effort on attracting and retaining passionate and motivated employees who want to play a role in helping people with serious health conditions and who see this effort as personally rewarding. In our highly entrepreneurial environment, employees are empowered and the opportunity for professional development occurs every day.
The Associate Director CMC Drug Substance works cross-functionally with internal and external teams to support drug substance (DS) GMP external clinical and commercial manufacturing, process technology transfer, process validation (PV), continuous process verification (CPV), preparing Module 3 of the CTD for commercialization of pipeline drug candidates while adhering to Good Manufacturing Practices, company policies and procedures.
Develops antibody-based therapies targeting inflammatory diseases
Celldex Therapeutics develops antibody-based therapies for inflammatory, allergic, and autoimmune diseases, focusing on mast cell biology. Its lead program barzolvolimab is a humanized monoclonal antibody that inhibits KIT, reducing mast cell activity and inflammation; its pipeline includes other antibodies designed to engage the immune system or modulate disease pathways. The company leverages partnerships and licensing in addition to developing its own therapies to create a breadth of programs in its target areas. Its goal is to deliver therapies that lessen inflammation and autoimmune activity by targeting mast cells and related signaling pathways.
Explore more opportunities at Celldex Therapeutics